Using a genetic test to manage heart and kidney complications in type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pragmatic trial aims to evaluate the effectiveness of a polygenic risk prediction test in managing cardiorenal complications in patients with type 2 diabetes (T2D). Participants will undergo saliva sampling to determine their genetic risk and will have regular clinic visits every three months for checkups and tests. The study will compare the achievement of therapeutic targets between patients who are informed of their genetic risk and those who are not, over an 18-month period. The goal is to improve management of blood glucose, blood pressure, and kidney function in high-risk patients through personalized treatment approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients with T2D of both sexes regardless of ethnicity, level of diabetes control and presence of complications.
* Able to visit the study site 7 times
* Able and willing to provide informed consent to the clinical and PRS parts of the study.

Exclusion Criteria:

* Any condition that may impact participation in a real-world study according to the treating physician.
* People with a high frailty index as no benefit of therapeutic intensification has been demonstrated in these diabetic patients.
* People who refuse to be informed of their cardiorenal risk score.

Where it's running

• Chum
  Montreal, Quebec, Canada Recruiting
• ELNA Medical
  Montreal, Quebec, Canada Not yet recruiting

Study contacts

• Principal investigator: Pavel Hamet, MD, PhD — Chum
• Study coordinator: Marie-Renée Guertin, il,cra
• Email: marie-renee.guertin.chum@ssss.gouv.qc.ca
• Phone: 514-249-4209

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based prediction of five major diseases using integrated health data

  Researchers are testing an AI model to see if they can predict the onset of five major diseases in adults 30–65 by combining medical records with biospecimens and lifestyle data.

  Recruiting Asan Medical Center · Seoul, Seoul Special City · NCT07595718

• Early risk screening for diabetes and heart disease in Ascoli Piceno

  This project tests a new screening program for 50-year-olds in Ascoli Piceno to see if they are at risk for type 2 diabetes and cardiovascular disease.

  Recruiting at 2 sites Marche Region Regional Health Agency · Ascoli Piceno, Ascoli Piceno and 1 other locations · NCT07344701

• Vicadrostat with empagliflozin for people with type 2 diabetes, high blood pressure, and heart disease

  This trial will test whether adding vicadrostat to empagliflozin lowers cardiovascular risk in adults who have type 2 diabetes, high blood pressure, and existing cardiovascular disease but no history of heart failure.

  Recruiting at 1096 sites Phase 3 Boehringer Ingelheim · Anniston, Alabama and 1141 other locations · NCT07064473

• Kefir for vascular and immune health in people with or at risk for type 2 diabetes

  This 12-week test will see if drinking 350 mL of traditional kefir each day helps improve blood vessel and immune health in adults aged 24–70 who have or are at higher risk for type 2 diabetes.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06695221

• Evaluating human placental membrane products for treating nonhealing diabetic foot and venous leg ulcers

  This study is testing whether using human placental products along with regular care can help people with stubborn diabetic foot and leg ulcers heal better.

  Recruiting C5 Biomedical · Metairie, Louisiana · NCT06674980

• Evaluating Enavogliflozin for Heart and Kidney Health in Type 2 Diabetes

  This study is testing if a new diabetes medication called enavogliflozin can improve heart and kidney health in adults with type 2 diabetes compared to other similar medications.

  Recruiting Phase 4 Yonsei University · Seoul · NCT06642623

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.